Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Japan.
J Pharm Pharmacol. 2012 May;64(5):677-87. doi: 10.1111/j.2042-7158.2011.01444.x. Epub 2012 Feb 7.
There is an inverse relationship between high-density lipoprotein (HDL) and heart disease. HDL possesses not only both antioxidant and anti-inflammatory properties, but also anti-thrombotic and endothelial function-promoting qualities. However, it is not only the serum concentration of HDL that is important, but also the 'functional' quality of the HDL. The objective was to determine the functional status of HDL in a well-established mouse model of dyslipidaemia and atherosclerosis induced by the administration of a block copolymer (poloxamer 407; P-407).
C57BL/6 mice were administered a single intraperitoneal dose of P-407 (0.5g/kg) and blood was collected at 24h post-dosing. HDL was isolated from controls (control HDL) and P-407-treated (P-407 HDL) mice and used to test its anti-inflammatory properties in vitro. Additionally, antioxidant enzymes associated with HDL, namely, platelet activating factor-acetylhydrolase (PAF-AH) and paraoxonase (PON), were evaluated for any potential reduction in their biological activity.
A single injection of P-407 in C57BL/6 mice resulted in a marked decrease in the levels of HDL-cholesterol and phospholipids. HDL particle size significantly increased, primarily due to remodelling of HDL with triglyceride. It was demonstrated that (i) long-chain saturated fatty acids were higher and the n-3/n-6 fatty acid ratio was significantly lower for P-407 HDL compared with control HDL, and (ii) P-407 HDL lost its capacity to inhibit tumour necrosis factor-α (TNF-α)-induced vascular cell adhesion molecule-1 (VCAM-1) expression compared with control HDL. Additionally, P-407 HDL was not able to neutralize lipopolysaccharide and inhibit subsequent TNF-α production compared with control HDL. The biological activity of platelet-activating factor acetylhydrolase (PAF-AH) and paraoxonase (PON) decreased in direct proportion to the circulating levels of both HDL-cholesterol and apolipoprotein (apoA-1).
Combination of previously reported findings in P-407-treated mice, such as (i) production of both oxidized LDL and malondialdehyde, and (ii) profound elevations in the soluble forms of intercellular adhesion molecule-1 (ICAM-1), VCAM-1, and E-selectin, with the present results, would strongly suggest that HDL in P-407-treated mice is rendered dysfunctional. Thus, these findings help to explain why P-407-treated mice begin to form aortic atherosclerotic lesions about one month after initiating P-407 treatment.
高密度脂蛋白(HDL)与心脏病呈负相关。HDL 不仅具有抗氧化和抗炎特性,还具有抗血栓形成和促进血管内皮功能的特性。然而,不仅是血清 HDL 浓度很重要,而且 HDL 的“功能”质量也很重要。本研究旨在通过给予嵌段共聚物(泊洛沙姆 407;P-407)建立的稳定的血脂异常和动脉粥样硬化小鼠模型来确定 HDL 的功能状态。
给予 C57BL/6 小鼠单次腹腔内 P-407(0.5g/kg)剂量,给药后 24 小时采集血液。从对照组(对照 HDL)和 P-407 处理组(P-407 HDL)的小鼠中分离 HDL,并在体外测试其抗炎特性。此外,还评估了与 HDL 相关的抗氧化酶,即血小板激活因子乙酰水解酶(PAF-AH)和对氧磷酶(PON),以评估其生物学活性是否降低。
单次给予 C57BL/6 小鼠 P-407 导致 HDL-胆固醇和磷脂水平显著降低。HDL 粒径显著增加,主要是由于 HDL 与甘油三酯的重塑。结果表明:(i)与对照 HDL 相比,P-407 HDL 中的长链饱和脂肪酸含量较高,n-3/n-6 脂肪酸比例显著降低,(ii)与对照 HDL 相比,P-407 HDL 抑制肿瘤坏死因子-α(TNF-α)诱导的血管细胞粘附分子-1(VCAM-1)表达的能力丧失。此外,与对照 HDL 相比,P-407 HDL 不能中和脂多糖并抑制随后的 TNF-α 产生。血小板激活因子乙酰水解酶(PAF-AH)和对氧磷酶(PON)的生物学活性与循环 HDL-胆固醇和载脂蛋白(apoA-1)水平呈直接比例下降。
将之前在 P-407 处理的小鼠中报告的发现(i)产生氧化的 LDL 和丙二醛,以及(ii)细胞间粘附分子-1(ICAM-1)、VCAM-1 和 E-选择素的可溶性形式的显著升高与本研究结果相结合,强烈表明 P-407 处理的小鼠中的 HDL 功能失调。因此,这些发现有助于解释为什么 P-407 处理的小鼠在开始 P-407 治疗后约一个月开始形成主动脉粥样硬化病变。